Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.

about

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.

P2860

Q33796590-28AAC516-199F-44E3-AC77-330CDE4A5688 Q37616815-6BD5BB63-CD4C-473D-ABFF-4880404A705A

P2860

Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.

Item

http://www.wikidata.org/entity/Q38384344

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Palifermin for prevention of o ...... tion retrospective evaluation.

@en

type

Item

label

Palifermin for prevention of o ...... tion retrospective evaluation.

@en

prefLabel

Palifermin for prevention of o ...... tion retrospective evaluation.

@en

P1476

Palifermin for prevention of o ...... tion retrospective evaluation.

@en

P2093

Andrew Dagis

http://www.w3.org/2001/XMLSchema#string

Diana T Nguyen

http://www.w3.org/2001/XMLSchema#string

Joel Epstein

http://www.w3.org/2001/XMLSchema#string

Joycelynne Palmer

http://www.w3.org/2001/XMLSchema#string

Ricardo Spielberger

http://www.w3.org/2001/XMLSchema#string

Sepideh Shayani

http://www.w3.org/2001/XMLSchema#string

Stephen J Forman

http://www.w3.org/2001/XMLSchema#string

P2860

Palifermin for oral mucositis after intensive therapy for hematologic cancers

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.

Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.

Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.

P2888

s00520-015-2688-7

P304

3141-3147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-2688-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25791390

http://www.w3.org/2001/XMLSchema#string

Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.

about

P2860

P2860

Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698